糖尿病的胰岛素治疗精编版.ppt

* the introduction of insulin represents a failure on the part of the patient to achieve good control of their diabetes, and introduction of insulin becomes a form of punishment because the patient has been on oral therapy for many years, there is no need for change because hypoglycemia is dangerous, it must be avoided at all costs in the older patient; thus, despite high glucose values, insulin should not be used by commencing insulin in a previously independent older patient, the patient may be considered “unfit” to live alone and thus forced into a nursing home environment * * * （红色及绿色都太深，换一种比较亮的颜色。另外，颜色不要太多。） * （图重画，清晰、明确、美观，早餐、午餐、晚餐的小碗重画，都应向前移一些，到竖线的旁边） * 64名2型老年糖尿病病人，交叉方式随机分为预混型胰岛素和自行混合胰岛素两组，每个疗程为8周 结果是，大部分使用预混胰岛素的患者认为很容易掌握。 * 诺和灵30R可以适用于大部分的2型糖尿病患者。 20名Ⅰ型糖尿病病人用预混型胰岛素（诺和灵?30R）与可溶性/低精蛋白锌按20/80-40/60比例自行混合治疗，为期8周的交叉对照研究。 红色曲线为使用诺和灵30R患者的全天血糖情况，白色曲线为使用20/80－40/60不同比例自行混合胰岛素患者的全天血糖情况。结果发现，使用诺和灵30R患者的血糖与使用其他不同比例自行混合胰岛素患者的血糖控制无明显差异，使用诺和灵30R可以覆盖80％2型糖尿病患者的血糖。 * * * * Manuscript submitted For the total population, the mean prandial glucose increment (ie, average taken for breakfast, lunch and dinner) was significantly less in patients treated with NovoMix 30 twice-daily compared with those receiving NPH twice-daily * # - at week 28, before breakfast BG values for glargine were significantly lower than in the NovoMix 20 group (p=0.0124) - at week 28, BG values before lunch, before dinner, after dinner and at bedtime were significantly lower for NovoMix 30 compared with glargine:before lunch, p=0.0002before dinner, p=0.0443after dinner, p0.0001at bedtime, p0.0001 * * 预混胰岛素类似物诺和锐?30与预混人胰岛素30R的区别在于: 诺和锐?30中含有诺和锐?30的是30%的门冬胰岛素和70%的精蛋白结合的结晶门冬胰岛素 预混人胰岛素30R中含有的是30%的可溶性人胰岛素和70%的中效胰岛素(NPH),正是由于它们预混成份的不同使得它们在药代及药效学上有着明显的区别. * * ANA 038 Comparison of the efficacy and safety of NovoMix? 30 and BHI 30 in a twice-daily meal-related regimen, in a mixed population of patients with type 1 and type 2 diabetes. In this 12-week, randomised, open labelled, parallel-group compar